大科学装置——重离子加速器，是应用于核物理研究、材料科学以及肿瘤治疗等领域的国之重器。全国 政协委员、中国科学院近代物理研究所副所长杨建成，多年来深耕重离子加速器的自主研发与成果转 化。 今年全国两会，杨建成将聚焦重离子加速器产业发展、临床应用等关键问题提出建议，让大国重器更好 服务社会、造福人民。 近日，杨建成专程来到位于兰州新区的一家高新技术企业走访调研。这家企业负责国产医用重离子装置 设备的全链条制造，在技术攻关和市场推广等方面，面临哪些难题，是杨建成这次调研的重点。 兰州某科技公司常务副总经理 姚俊杰：随着我们整个重离子产业的日趋完善，我们现在在推广的过程 中，要引进社会资本去办医，这样能把民间资本跟社会资本，纳入整个国家的医疗体系。 杨建成作为中国首台医用重离子加速器的核心研发者之一，始终密切关注治疗装置的运行和治疗效果。 在武威重离子中心，杨建成与医护团队交流，详细了解我国首台拥有自主知识产权的医用重离子加速器 的运行情况。截至目前，这台装置已完成2400多例疑难肿瘤的治疗。 武威肿瘤医院副院长 张雁山：在我们面前的这个治疗台控制的是1号室和2号室，目前所有都是远程化 操作，在这对位、对线，位置非 ...

内容概要：MRI超导磁体是指用于MRI设备的超导磁体，由于磁共振需要在高均匀、高稳定的强磁场中 才能实现，磁体用于提供MRI成像所必需的磁场，是MRI设备最重要的组成部分之一。近年来，随着国 内MRI超导磁体领域国产替代进程的持续深化与加速落地，国内企业在无液氦技术量产、高场强磁体性 能优化等核心环节实现关键突破，头部厂商纷纷推进智能化生产线建设与产能扩建，同时上游超导材 料、精密制冷部件等配套产业链的国产化率大幅提升，为行业供给端的扩容提供了坚实支撑。在此背景 下，行业整体供给能力与供给质量同步升级，供给规模稳步扩大，国内MRI超导磁体行业需求趋于稳 定。2025年，我国MRI超导磁体行业产能增长至1400台，产量增长至900台,行业需求量增长至1549台， 市场规模增长至30.32亿元；预计2026年，我国MRI超导磁体行业产能将增长至1500台，产量将增长至 985台，行业需求量增长至1638台，市场规模增长至32.35亿元。 上市企业：健信超导[688805]、联影医疗[688271]、西部超导[688122]、辰光医疗[920300] 相关企业：潍坊新力超导磁电科技有限公司、西门子医疗、GE医疗、飞 ...

Core Insights - Guoke Ion Medical Technology Co., Ltd. has successfully raised 800 million yuan in its first round of equity financing, led by the Social Security Fund's Zhongguancun Independent Innovation Special Fund and Junlian Capital, with additional investment from existing shareholder Xiamen Guomao [1][2] Group 1: Company Overview - Guoke Ion aims to create a comprehensive heavy ion therapy industry that integrates high-end equipment manufacturing, precision digital healthcare, and operational maintenance services [1] - The company focuses on merging advanced medical technology with finance and services to provide a full-process solution for ion therapy, including equipment layout, financial support, operation and maintenance, consulting services, personnel training, and big data services [1] Group 2: Product Development - The company has invested significantly in R&D for new products, recently developing the world's first light ion combined treatment device, which can provide proton and helium ion beams at 230 MeV/u for clinical treatment, as well as carbon ion beams for tumor treatment in specific body areas [1] - The new device occupies only 1500 m² and significantly reduces equipment and construction costs compared to traditional heavy ion therapy devices, addressing the high comprehensive investment issue associated with ion therapy [1] Group 3: Strategic Investment and Goals - The introduction of strategic investors will help Guoke Ion strengthen its core technological advantages, accelerate international market expansion, and stabilize its strategic planning while improving corporate governance [2] - The company plans to leverage its AI center to connect ion therapy devices nationwide, gather quality medical resources, and reconstruct the diagnosis and treatment process using intelligent technology to achieve strategic goals [2]

Core Insights - The Sudanese Prime Minister Idris conducted an inspection of the Jiad Industrial Zone in Khartoum, which includes various sectors such as tractors and agricultural equipment, furniture and medical equipment, as well as metal forming and small machinery manufacturing [1] Industry Summary - The Jiad Industrial Zone encompasses multiple sectors, indicating a diversified industrial base that includes agricultural machinery, furniture production, medical equipment manufacturing, and metalworking [1]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has released a guideline to standardize pricing for surgical and treatment auxiliary services, addressing the challenge of charging for advanced medical technologies like surgical robots and 3D bioprinting [1][2]. Group 1: Pricing Guidelines - The guideline establishes 37 pricing items, including 5 additional charges and 1 expansion item, covering key technologies such as 3D printing, surgical robots, and remote surgeries [1]. - A specific pricing project for bioprinting has been created to facilitate the transition from concept testing to clinical application, promoting the use of organ-like technologies [1]. - The guideline introduces a tiered pricing model for surgical robots based on their level of involvement and clinical value, allowing for higher fees for more advanced functionalities [2]. Group 2: Impact on Companies - Companies involved in 3D bioprinting have expressed that the guideline significantly aids their operations, as the lack of standardized pricing previously hindered clinical entry and long-term development [1]. - The guideline is expected to encourage innovation and shorten the promotion cycle for new technologies, benefiting domestic supply chains and reducing costs [2]. - The release of the guideline is anticipated to resolve clinical translation issues for innovative technologies, allowing patients to benefit from advancements while promoting high-quality development in the medical equipment industry [2]. Group 3: Remote Surgery - The guideline includes a pricing project for remote surgical assistance, enabling experts in resource-rich areas to provide services to patients in other regions, thus alleviating the burden of seeking medical care from afar [3]. - A notable achievement in remote surgery was highlighted, where a team successfully performed a prostate cancer surgery over a distance of 8,100 kilometers using a domestic surgical robot [3]. - The market share of domestic laparoscopic surgical robots is projected to grow significantly, from 32.61% in 2023 to 48.89% in 2024, indicating a strong potential for future expansion [3].

Core Viewpoint - The company reported a decline in revenue and net profit for the first three quarters of 2025, but showed significant growth in net profit for the third quarter, indicating potential recovery and strategic focus on key business areas [1]. Financial Performance - The company achieved an operating income of 318 million yuan for the first three quarters of 2025, a decrease of 14.52% compared to the same period last year [1]. - The net profit attributable to shareholders was 24.6 million yuan, down 2.38% year-on-year [1]. - In the third quarter alone, the net profit attributable to shareholders increased by 61.24% year-on-year, while the net profit excluding non-recurring items grew by 107.84% [1]. Business Development - The company focuses on two main business segments: micro-special motors and components, and precision drug delivery devices [1]. - In the micro-special motors and components segment, the company is enhancing its market presence by deepening relationships with existing clients and actively seeking new customers, while also shifting towards higher-end industry fields [1]. - The company is accelerating the automation and intelligent production transformation of micro-special motors to reduce costs and improve product competitiveness [1]. - In the precision drug delivery devices segment, the company is strengthening collaboration with existing strategic clients, increasing customer loyalty, and actively engaging with new clients, with several customized projects entering the testing and validation phase [1].

Core Viewpoint - The article discusses the "2026 Tariff Adjustment Plan" released by the State Council Tariff Commission, which will be implemented starting January 1, 2026, focusing on tariff reductions for various instruments related to measurement, medical, and industrial testing categories [1][20]. Group 1: Core Instrument Categories - Measurement/Metrology Instruments include items such as coordinate measuring machines, programmable logic controllers (PLC), and gas flow valves specifically for semiconductor/integrated circuit manufacturing [1][2]. - Medical Instruments and Components cover devices like medical linear accelerators, digital X-ray imaging systems, and diagnostic kits for various diseases [8]. - Industrial Testing/Processing Instruments are also included, although specific examples are not detailed in the provided text [3]. Group 2: Tariff Adjustments - The adjustment plan includes a reduction in tariffs for 935 items, excluding tariff quota goods, with specific reductions for key components and advanced materials [9][10]. - Tariffs on medical products such as artificial blood vessels and certain diagnostic kits will also be lowered, enhancing the affordability of these essential items [12]. - The plan aims to stimulate domestic consumption by reducing import costs, with an expected increase in import volumes by 15-20% for related categories due to lower tariffs [6]. Group 3: Special Tariff Rates - The plan continues to provide zero-tariff treatment for 100% of products from 43 least developed countries, maintaining preferential tariff rates for certain imports from ASEAN member countries and other trade partners [19][18]. - The agreement includes further tariff reductions based on existing free trade agreements with countries like New Zealand, Peru, and Australia, among others [17].

Core Points - Hainan Free Trade Port has officially launched its full island closure, becoming a special customs supervision area with a policy characterized by "one line open, one line controlled, and free movement within the island" [1] - The first batch of "zero tariff" imported products, including 179,000 tons of petrochemical raw materials, has arrived at Yangpu Port, significantly reducing customs clearance time by nearly 4 hours [1][3] - The list of "zero tariff" goods has expanded to approximately 6,600 tax items, broadening the scope of beneficiaries [3] Customs and Trade Facilitation - To ensure smooth customs clearance for the first batch of goods post-closure, high-frequency scheduling and tailored service strategies have been implemented [3] - The first batch of "zero tariff" goods, including a set of imported scientific research equipment valued at 1 million yuan, has completed customs clearance at Sanya Phoenix Airport, saving over 180,000 yuan in procurement costs [5] - The processing and value-added internal sales tax exemption policy has been optimized, allowing products with over 30% value-added to enter the mainland market duty-free [9] Economic Impact and Future Prospects - The expansion of the "zero tariff" policy is expected to lower procurement costs for enterprises, enabling them to invest more in research and production, thereby enhancing innovation [7] - The closure marks the beginning of a new phase in the construction of Hainan Free Trade Port, with plans to continuously expand open fields and improve policy systems [14] - The Hainan Provincial Development and Reform Commission aims to promote foreign investment and enhance the convenience of foreign investment, striving to create a modern industrial system with Hainan characteristics [14]

Group 1: Financial Support and Impact - Postal Savings Bank of China Jiangxi Branch has focused on serving the real economy by providing targeted financial resources to key areas of county economic development, resulting in an agricultural loan balance of nearly 106.5 billion yuan and inclusive small and micro enterprise loans exceeding 78.5 billion yuan by the end of November 2025 [1] - The bank has implemented a customized financial service model, creating exclusive financial product solutions tailored to the unique agricultural industry layout in Jiangxi Province, particularly focusing on five major industrial chains and two characteristic industrial chains [1] - The bank's support has enabled companies like Guodu Traditional Chinese Medicine to secure timely funding, which has been crucial for their growth and operational needs, demonstrating the bank's role in facilitating business development during critical periods [2][3] Group 2: Industry Development and Innovation - Guodu Traditional Chinese Medicine has invested over 100 million yuan in modernizing its pharmaceutical workshop and research center, showcasing the integration of traditional practices with modern technology, supported by Postal Savings Bank [3] - Tianyu Oil Co., Ltd. has expanded its product range and enhanced its production capabilities through financial backing from the bank, which has allowed for increased research and development and digital transformation [4][5] - Jiangxi Hongcheng Aluminum Co., Ltd. has benefited from a tailored financial service plan that addresses its specific needs for high-end technology and equipment, enabling it to pursue a green development strategy [6] Group 3: Support for Green and Sustainable Development - Postal Savings Bank Jiangxi Branch has established a comprehensive financial service system to support traditional industry upgrades and technological innovation, focusing on green and low-carbon economic initiatives [7] - The bank has actively engaged with local governments and businesses to provide diversified financing solutions, thereby promoting the development of the circular economy and supporting green industries [6][7] - Jiangxi Dertai Technology Co., Ltd. has received significant financial support for its expansion projects, reflecting the bank's commitment to fostering innovation in the medical equipment sector [8] Group 4: Tailored Financial Products for Specific Industries - The bank has developed specialized loan products, such as the "Metal Furniture Industry Loan," to better match the financial needs of small and micro enterprises in the metal furniture sector, addressing challenges like insufficient collateral [9][10] - Through initiatives like "Hundred Banks Enter Ten Thousand Enterprises," the bank has conducted in-depth visits to understand the operational status and funding needs of private enterprises, allowing for customized financing solutions [10]

Core Viewpoint - Japan is increasingly concerned about its reliance on Chinese rare earth exports and is taking measures to diversify supply sources and develop alternative materials [1][2] Group 1: Japan's Dependence on Rare Earths - Japan's dependence on Chinese rare earth imports has decreased from approximately 90% to around 60% [1] - Despite the reduction, Japan remains highly dependent on critical rare earth elements like Dysprosium (Dy) and Terbium (Tb), which are essential for electric vehicle drive motors [1] Group 2: Economic Impact of Potential Export Controls - If China implements export controls, five key sectors in Japan—automotive, electronics, wind power, medical devices, and aerospace—will be significantly affected [2] - The automotive industry, particularly electric and hybrid vehicles, relies heavily on rare earth magnets, and past shortages have led to production halts [2] - In the electronics sector, rare earths are crucial for smartphones, semiconductor manufacturing, and hard drives, with China dominating the refining process [2] - Wind power equipment and medical devices, such as MRI machines, also have high dependencies on rare earths, with limited alternatives available [2] - The aerospace sector uses rare earth alloys and magnets extensively, with minimal room for substitution [2] Group 3: Estimated Economic Losses - If Chinese rare earth export restrictions last for three months, Japan's economic loss is estimated at approximately 660 billion yen, equating to a 0.11% decline in nominal and real GDP [2] - Should the restrictions persist for one year, the economic loss could escalate to about 2.6 trillion yen, resulting in a GDP decline of 0.43% [2]